Cargando…
Targeting intracellular Neu1 for coronavirus infection treatment
There are currently no effective therapies for COVID-19 or antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and vaccines appear less effective against new SARS-CoV-2 variants; thus, there is an urgent need to understand better the virulence mechanisms of SARS-CoV-2 an...
Autores principales: | Yang, Darong, Wu, Yin, Turan, Isaac, Keil, Joseph, Li, Kui, Chen, Michael H., Liu, Runhua, Wang, Lizhong, Sun, Xue-Long, Chen, Guo-Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870608/ https://www.ncbi.nlm.nih.gov/pubmed/36714013 http://dx.doi.org/10.1016/j.isci.2023.106037 |
Ejemplares similares
-
Selective Response to Bacterial Infection by Regulating Siglec-E Expression
por: Wu, Yin, et al.
Publicado: (2020) -
Targeted disruption of Rab1a causes early embryonic lethality
por: Wu, Yin, et al.
Publicado: (2022) -
Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS
por: Boligan, Kayluz F., et al.
Publicado: (2020) -
Anti-Neu5Gc and anti-non-Neu5Gc antibodies in healthy humans
por: Gao, Bingsi, et al.
Publicado: (2017) -
Planung neu denken!
por: Schäffer, Utz, et al.
Publicado: (2020)